Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer

Stacey L. Berg, Anthony Tolcher, Joyce A. O'Shaughnessy, Andrea M. Denicoff, Marianne Noone, Frederick P. Ognibene, Kenneth H. Cowan, Frank M. Balis

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purpose: To study the effect of the multidrug-resistance reversal agent R- verapamil on the pharmacokinetic behavior of paclitaxel. Methods: Six women with breast cancer who received paclitaxel as a 3-hour infusion with and without R-verapamil were monitored with frequent plasma sampling up to 24 hours postinfusion. Paclitaxel concentrations were measured using a reverse- phase high-pressure liquid chromatography assay. Results: Concomitant administration of R-verapamil resulted in a decrease in mean (± SD) paclitaxel clearance from 179 ± 67 mL/min/m2 to 90 ± 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]). The mean end-infusion paclitaxel concentration was also twofold higher: 5.1 ± 1.8 μmol/L versus 11.3 ± 4.1 μmol/L (P < .03). Conclusion: The alteration in paclitaxel pharmacokinetics when paclitaxel and R-verapamil are coadministered complicates the interpretation of response and toxicity data from clinical trials of this drug combination.

Original languageEnglish (US)
Pages (from-to)2039-2042
Number of pages4
JournalJournal of Clinical Oncology
Volume13
Issue number8
DOIs
StatePublished - Aug 1995

Fingerprint

Verapamil
Paclitaxel
Pharmacokinetics
Breast Neoplasms
Multiple Drug Resistance
Drug Combinations
Reverse-Phase Chromatography
Area Under Curve
High Pressure Liquid Chromatography
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Berg, S. L., Tolcher, A., O'Shaughnessy, J. A., Denicoff, A. M., Noone, M., Ognibene, F. P., ... Balis, F. M. (1995). Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. Journal of Clinical Oncology, 13(8), 2039-2042. https://doi.org/10.1200/JCO.1995.13.8.2039

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. / Berg, Stacey L.; Tolcher, Anthony; O'Shaughnessy, Joyce A.; Denicoff, Andrea M.; Noone, Marianne; Ognibene, Frederick P.; Cowan, Kenneth H.; Balis, Frank M.

In: Journal of Clinical Oncology, Vol. 13, No. 8, 08.1995, p. 2039-2042.

Research output: Contribution to journalArticle

Berg, SL, Tolcher, A, O'Shaughnessy, JA, Denicoff, AM, Noone, M, Ognibene, FP, Cowan, KH & Balis, FM 1995, 'Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer', Journal of Clinical Oncology, vol. 13, no. 8, pp. 2039-2042. https://doi.org/10.1200/JCO.1995.13.8.2039
Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. Journal of Clinical Oncology. 1995 Aug;13(8):2039-2042. https://doi.org/10.1200/JCO.1995.13.8.2039
Berg, Stacey L. ; Tolcher, Anthony ; O'Shaughnessy, Joyce A. ; Denicoff, Andrea M. ; Noone, Marianne ; Ognibene, Frederick P. ; Cowan, Kenneth H. ; Balis, Frank M. / Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 8. pp. 2039-2042.
@article{7d4d74b367ac4d38b402d2ac4b43e3c9,
title = "Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer",
abstract = "Purpose: To study the effect of the multidrug-resistance reversal agent R- verapamil on the pharmacokinetic behavior of paclitaxel. Methods: Six women with breast cancer who received paclitaxel as a 3-hour infusion with and without R-verapamil were monitored with frequent plasma sampling up to 24 hours postinfusion. Paclitaxel concentrations were measured using a reverse- phase high-pressure liquid chromatography assay. Results: Concomitant administration of R-verapamil resulted in a decrease in mean (± SD) paclitaxel clearance from 179 ± 67 mL/min/m2 to 90 ± 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]). The mean end-infusion paclitaxel concentration was also twofold higher: 5.1 ± 1.8 μmol/L versus 11.3 ± 4.1 μmol/L (P < .03). Conclusion: The alteration in paclitaxel pharmacokinetics when paclitaxel and R-verapamil are coadministered complicates the interpretation of response and toxicity data from clinical trials of this drug combination.",
author = "Berg, {Stacey L.} and Anthony Tolcher and O'Shaughnessy, {Joyce A.} and Denicoff, {Andrea M.} and Marianne Noone and Ognibene, {Frederick P.} and Cowan, {Kenneth H.} and Balis, {Frank M.}",
year = "1995",
month = "8",
doi = "10.1200/JCO.1995.13.8.2039",
language = "English (US)",
volume = "13",
pages = "2039--2042",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer

AU - Berg, Stacey L.

AU - Tolcher, Anthony

AU - O'Shaughnessy, Joyce A.

AU - Denicoff, Andrea M.

AU - Noone, Marianne

AU - Ognibene, Frederick P.

AU - Cowan, Kenneth H.

AU - Balis, Frank M.

PY - 1995/8

Y1 - 1995/8

N2 - Purpose: To study the effect of the multidrug-resistance reversal agent R- verapamil on the pharmacokinetic behavior of paclitaxel. Methods: Six women with breast cancer who received paclitaxel as a 3-hour infusion with and without R-verapamil were monitored with frequent plasma sampling up to 24 hours postinfusion. Paclitaxel concentrations were measured using a reverse- phase high-pressure liquid chromatography assay. Results: Concomitant administration of R-verapamil resulted in a decrease in mean (± SD) paclitaxel clearance from 179 ± 67 mL/min/m2 to 90 ± 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]). The mean end-infusion paclitaxel concentration was also twofold higher: 5.1 ± 1.8 μmol/L versus 11.3 ± 4.1 μmol/L (P < .03). Conclusion: The alteration in paclitaxel pharmacokinetics when paclitaxel and R-verapamil are coadministered complicates the interpretation of response and toxicity data from clinical trials of this drug combination.

AB - Purpose: To study the effect of the multidrug-resistance reversal agent R- verapamil on the pharmacokinetic behavior of paclitaxel. Methods: Six women with breast cancer who received paclitaxel as a 3-hour infusion with and without R-verapamil were monitored with frequent plasma sampling up to 24 hours postinfusion. Paclitaxel concentrations were measured using a reverse- phase high-pressure liquid chromatography assay. Results: Concomitant administration of R-verapamil resulted in a decrease in mean (± SD) paclitaxel clearance from 179 ± 67 mL/min/m2 to 90 ± 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]). The mean end-infusion paclitaxel concentration was also twofold higher: 5.1 ± 1.8 μmol/L versus 11.3 ± 4.1 μmol/L (P < .03). Conclusion: The alteration in paclitaxel pharmacokinetics when paclitaxel and R-verapamil are coadministered complicates the interpretation of response and toxicity data from clinical trials of this drug combination.

UR - http://www.scopus.com/inward/record.url?scp=0029165482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029165482&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.8.2039

DO - 10.1200/JCO.1995.13.8.2039

M3 - Article

C2 - 7636546

AN - SCOPUS:0029165482

VL - 13

SP - 2039

EP - 2042

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -